8-K: Cerus Corporation Reports Strong Q3 2024 Results, Raises Full-Year Revenue Guidance

Cerus Corporation announced a 16% increase in third-quarter product revenue and raised its full-year 2024 product revenue guidance to $177-$179 million.

Summary

• Cerus Corporation reported its financial results for the third quarter of 2024, showing a 16% increase in product revenue compared to the same period last year, reaching $46 million.
• The company's total revenue for the quarter was $50.7 million, a 7% increase year-over-year.
• Product revenue for the first nine months of 2024 increased by 18% to $129.5 million.
• Government contract revenue decreased by 38% in the third quarter to $4.6 million due to the completion of the U.S. Phase 3 ReCePI clinical trial for INTERCEPT RBCs.
• The company narrowed its GAAP net loss to $2.9 million and achieved a positive non-GAAP adjusted EBITDA of $4.4 million for the quarter.
• Cerus generated positive operating cash flows for the third consecutive quarter, bringing the year-to-date total to $6.4 million.
• The company has raised its full-year 2024 product revenue guidance to a range of $177 million to $179 million and increased the lower end of its INTERCEPT Fibrinogen Complex (IFC) revenue guidance to $9 million to $10 million.
• Cerus has partnered with BARDA for a new six-year contract worth up to $248 million to support the advancement of INTERCEPT Blood System for Red Blood Cells (RBCs).
• The CE Mark review for INTERCEPT RBCs concluded without approval, and the company is assessing its strategy for future regulatory submission.
• The company has expanded its U.S. manufacturing capacity for IFC following the receipt of three additional BLA approvals by Cerus IFC production partners.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, improved profitability, and a significant BARDA contract. However, the delay in CE Mark approval for RBCs and the ongoing net loss temper the overall optimism.

Positives

• Product revenue saw a significant increase of 16% in Q3 and 18% for the first nine months of 2024.
• The company achieved positive non-GAAP adjusted EBITDA of $4.4 million in Q3, a substantial improvement from a loss of $1.0 million in the same period last year.
• Cerus generated positive operating cash flows for the third consecutive quarter, indicating improved financial health.
• The company has raised its full-year product revenue guidance, reflecting confidence in future growth.
• The new BARDA contract provides significant funding and support for the development of the INTERCEPT RBC system.
• Product gross margin improved to 56.9%, indicating better profitability.
• The company narrowed its net loss significantly, showing progress towards profitability.
• The expansion of U.S. manufacturing capacity for IFC will help meet growing demand.
• The company has submitted a CE Mark dossier for its LED illuminator, a new technology platform.

Negatives

• Government contract revenue decreased by 38% in the third quarter due to the completion of the U.S. Phase 3 ReCePI clinical trial for INTERCEPT RBCs.
• The CE Mark review for INTERCEPT RBCs concluded without approval, requiring a reassessment of the regulatory strategy.
• Total operating expenses decreased by 8%, but SG&A expenses increased due to non-cash stock-based compensation.
• The company still reported a net loss of $2.9 million for the quarter, although it is a significant improvement from the previous year.

Risks

• The company faces risks associated with the commercialization and market acceptance of the INTERCEPT Blood System.
• There are risks related to the uncertain and time-consuming regulatory process, including potential delays in obtaining approvals.
• The company is reliant on third parties for manufacturing, marketing, and distribution.
• There are risks associated with macroeconomic developments, including military conflicts and the COVID-19 pandemic.
• The company's ability to access additional funds under its credit facility and meet debt service obligations is a risk.
• The new BARDA contract is subject to the uncertain nature of government funding and may be terminated at any time for convenience.
• The company faces risks related to product safety, including the risk that septic platelet transfusions may not be avoidable with the INTERCEPT Blood System.
• The company is exposed to risks related to adverse market and economic conditions, including fluctuations in foreign exchange rates and weakening economic conditions.

Future Outlook

Cerus has raised its full-year 2024 product revenue guidance to a range of $177 million to $179 million and expects to achieve non-GAAP adjusted EBITDA breakeven for the full year. The company anticipates an enhanced regulatory submission for the INTERCEPT RBC system in Europe and expects to incorporate the ReCePI Phase 3 clinical data.

Management Comments

• William Obi Greenman, Cerus president and chief executive officer, stated that the company's performance was very strong for the third quarter.
• Greenman also mentioned that the company is pleased to have secured additional U.S. manufacturing capacity for IFC.
• Greenman noted that the company is on track to hit its full-year 2024 goals.
• Greenman highlighted the submission of the LED illuminator regulatory filing in Europe and the continued focus on the RBC program.

Industry Context

This announcement reflects a positive trend in the blood safety market, with increased demand for pathogen reduction technologies. Cerus's growth in product revenue and improved profitability align with the broader industry focus on enhancing blood safety and reducing transfusion-related risks. The partnership with BARDA also highlights the importance of government support in advancing innovative medical technologies.

Comparison to Industry Standards

• Cerus's 16% product revenue growth in Q3 is strong compared to some of its competitors in the blood safety market, such as Haemonetics, which has seen more modest growth in recent quarters.
• The improvement in gross margin to 56.9% is a positive sign, placing Cerus in a competitive position compared to companies with similar product offerings.
• The positive adjusted EBITDA of $4.4 million is a significant improvement and indicates that Cerus is moving towards profitability, which is a key metric for investors in the medical technology sector.
• The BARDA contract is a significant win for Cerus, providing a substantial funding opportunity that is not common for all companies in this space, giving them a competitive advantage.
• The delay in CE Mark approval for INTERCEPT RBCs is a setback, as competitors with approved RBC pathogen reduction systems in Europe may have a temporary advantage.

Stakeholder Impact

• Shareholders will likely react positively to the increased revenue guidance and improved profitability.
• Employees may benefit from the company's growth and positive financial performance.
• Customers will have access to increased supply of INTERCEPT Fibrinogen Complex.
• The BARDA contract will support the development of new products, potentially benefiting patients in the future.

Next Steps

• Cerus will assess its strategy for potential future regulatory submission for INTERCEPT RBCs in Europe.
• The company will continue to expand its U.S. manufacturing capacity for IFC.
• Cerus will continue to work with BARDA to advance the INTERCEPT Blood System for RBCs.
• The company will focus on achieving non-GAAP adjusted EBITDA breakeven for the full-year 2024.

Key Dates

Keywords

Cerus Corporation, INTERCEPT Blood System, Pathogen Reduction, Product Revenue, EBITDA, BARDA, Red Blood Cells, Platelets, Fibrinogen Complex, Regulatory Approval, Manufacturing Capacity, Gross Margin